Skip to main content
. 2013 Aug 12;8(8):e71441. doi: 10.1371/journal.pone.0071441

Figure 3. Effect of the adenylyl cyclase inhibitor SQ22536 on refraction, vitreous chamber depth (VCD), and axial length (AL).

Figure 3

(A–C) In normal eyes, subconjunctival injection of 100 µM SQ22536 had no significant effect on refraction, vitreous chamber depth (VCD) or axial length (AL). In FDM eyes, SQ22536 reduced (D) refraction (*: p<0.05, ***: p<0.001, independent sample t-test), (E) VCD (***: p<0.001, independent sample t-test), and (F) AL (**: p<0.01, ***: p<0.001, independent sample t-test) in a time-dependent manner. (Normal groups: non-injection n = 11, vehicle n = 14, 100 µM SQ22536 n = 17; FDM groups: FDM+non-injection n = 16, FDM+vehicle n = 17, FDM+100 µM SQ22536 n = 21).